EUCTR2006-000320-14-IT进行中（未招募）不适用
FACT anastrozole monotherapy versus maximal oestrogen blockade with anstrozole and fulvestrant combination therapy an open randomized, comparative, phase III multicentre study in postmenopausal women with hormone receptor positive breast cancer in first relapse after primary treatment of localized tumour. - FACT
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- ASTRAZENECA
- 入组人数
- 512
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1. Postmenopausal woman 2. Documented positive hormone receptor status ER ve and/or PgR ve of primary or metastatic tumour tissue 3. Patients with misurable or not misurable advanced disease 4. Histological/cytological confirmation of breast cancer 5. Provision of written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Previous systemic therapy for advanced breast cancer. 2. Platelets 100 109 / L 3. Total bilirubin 1.5 ULRR Upper limit of reference range 4. ALT or AST transamminase 2.5 ULRR if no demonstrable liver metastases or 5 ULRR in presence of liver metastases
研究者
相似试验
进行中（未招募）
1 期
Anastrozole monotherapy versus maximal oestrogen blockage with anastrozole and fulvestrant comination therapy: An open, randomised, comparative, phase III multicentre study in postmenopausal women with hormone receptor positive breast cancer in first relapse after primary treatment of localised tumour. - FACTEUCTR2006-000320-14-FRAstraZeneca AB512
进行中（未招募）
1 期
Anastrozole monotherapy versus maximal oestrogen blockage with anastrozole and fulvestrant comination therapy: An open, randomised, comparative, phase III multicentre study in postmenopausal women with hormone receptor positive breast cancer in first relapse after primary treatment of localised tumour. - FACTHormone receptor positive breast cancer in first relapse after primary treatment of localised tumour, in postmenopausal women.EUCTR2006-000320-14-FIAstraZeneca oy512
进行中（未招募）
不适用
Anastrozole monotherapy versus maximal oestrogen blockage with anastrozole and fulvestrant comination therapy: An open, randomised, comparative, phase III multicentre study in postmenopausal women with hormone receptor positive breast cancer in first relapse after primary treatment of localised tumour. - FACTEUCTR2006-000320-14-ISAstraZeneca512
进行中（未招募）
不适用
Anastrozole monotherapy versus maximal oestrogen blockage with anastrozole and fulvestrant combination therapy: An open, randomised, comparative, phase III multicentre study in postmenopausal women with hormone receptor positive breast cancer in first relapse after primary treatment of localised tumour. - FACTHormone receptor positive breast cancer in first relapse after primary treatment of localised tumour, in postmenopausal women.EUCTR2006-000320-14-PTAstraZeneca Produtos Farmacêuticos Lda512
已完成
3 期
Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination TherapyBreast CancerNCT00256698AstraZeneca514